Stock Notes

Alkem Laboratories

Every Finvezto stock note on Alkem Laboratories, dated and newest first. Coverage spans pharmaceuticals, pharma.

3 notes and counting
16 Sep 2026
Alkem Laboratories launched NeuCeno, the first cenobamate brand in India, for partial-onset seizures in adults.
The once-daily oral anti-seizure therapy comes in six strengths from 12.5 mg to 200 mg. India has an estimated 9.4 million people living with epilepsy.
08 Sep 2026
Alkem Laboratories launched Renocia Exo, which it calls India's first patented ginsenoside exosome based hair growth serum.
The formulation combines phyto-exosomes, biomimetic peptides and copper peptides. It extends Alkem's push into dermatology, a self-pay category that prices better than acute therapy.
03 Jun 2026
Alkem Laboratories launched a single-shot semaglutide pre-filled syringe at ₹350, the first such format commercially available in India.
Over 50 generic semaglutide brands entered the market after Novo Nordisk's Indian patent expired on March 21, 2026.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.